Biliary Tumor – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Biliary Tumor – Drugs In Development, 2024 report and make more profitable business decisions.
Bile duct cancer, or cholangiocarcinoma, is a rare malignancy arising from malignant cells forming in the bile ducts. It presents in two main types: intrahepatic, occurring inside the liver, and extrahepatic, forming outside the liver. Extrahepatic bile duct cancer further divides into perihilar, found where the right and left bile ducts meet, and distal, located where liver and gallbladder ducts merge. Symptoms include jaundice, dark urine, abdominal pain, fever, itchy skin, nausea, vomiting, and unexplained weight loss. These signs, while indicative of bile duct cancer, may also stem from other conditions, emphasizing the importance of consulting a doctor for a thorough evaluation.
The Biliary Tumor drugs in development market research report provide comprehensive information on the therapeutics under development for Biliary Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Biliary Tumor and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Biliary Tumor | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 22 molecules, with 20 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Biliary Tumor therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Biliary Tumor pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Biliary Tumor treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Bayer AGMerck & Co Inc
Mirati Therapeutics Inc
Multitude therapeutics Inc
Mundipharma EDO GmbH
Novartis AG
Oncocross Co Ltd
Pharma Mar SA
Processa Pharmaceuticals Inc
Redx Pharma Plc
Senhwa Biosciences Inc
SOTIO Biotech AS
Spark Biopharma Inc
Sunho (China) Biopharmaceutical Co Ltd
Taiho Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
tella Inc
TOT Biopharm Co Ltd
Transcenta Holding Ltd
University of Texas Health Science Center at San Antonio
Waterstone Hanxbio Pty Ltd
Xuzhou Medical University
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Biliary Tumor reports